Medicinal composition for treating vagina disease

A technique for vaginal diseases and compositions, applied in the field of pharmaceutical compositions

Inactive Publication Date: 2006-10-25
BEIJING JINCHENG TAIER PHARMA CO LTD
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report or corresponding technical inspiration on the combined use of nifuratel, nystatin and promestriene in the treatment of vaginal diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1 - Formulation 1

[0019] Mix 30g of nifuratel, 3g of nystatin (1mg titer is equivalent to 5000 nystatin units), 0.8g of promestriene, and then mix the mixture with 17.9g of β-cyclodextrin as a coating Mix and grind the mixture to make β-CD clathrate, then grind and mix the clathrate with 163.5g of semi-synthetic fatty acid fat melted in a water bath at 60-80°C and slightly cooled, when the temperature drops to 40°C, pour Put it in a suppository mold coated with paraffin oil, scrape off the excess after cooling, take out the formed suppository, and pack to make 100 vaginal controlled-release suppositories, so that each capsule contains 0.3g of nifuratel, 150,000 IU of nystatin and Promestriene 8mg.

Embodiment 2

[0020] Example 2 - Recipe 2

[0021] Mix 50g of nifuratel, 3g of nystatin (1mg titer is equivalent to 5000 nystatin units), 0.8g of promestriene, and then mix the mixture with 26.9g of β-cyclodextrin as a coating The mixture is mixed and ground to form a composite β-CD inclusion compound, and then the inclusion compound is ground and mixed with 246g of semi-synthetic fatty acid fat melted in a water bath at 60-80°C and slightly cooled. When the temperature drops to 40°C, pour Put it in a suppository mold coated with paraffin oil, scrape off the excess after cooling, take out the shaped suppository, and pack it to make 100 vaginal controlled-release suppositories, so that each capsule contains 0.5g of nifuratel, 150,000 IU of nystatin and Promestriene 8mg.

Embodiment 3

[0022] Example 3 - Recipe 3

[0023] Mix 30g of nifuratel, 4g of nystatin (1mg is equivalent to 5000 nystatin units), 1g of promestriene, and then mix the mixture with 17.5g of β-cyclodextrin as an inclusion agent Mix and grind to make a complex β-CD inclusion compound, then grind and mix the inclusion compound with 230g of semi-synthetic fatty acid fat melted in a water bath at 60-80°C and slightly cooled, and pour it into In the suppository mold coated with paraffin oil, scrape off the excess part after cooling, take out the formed suppository, and pack to make 100 vaginal controlled-release suppositories, so that each capsule contains 0.3g of nifuratel, 200,000 IU of nystatin and promethazine. Estrone 10mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a medicine composition for curing vaginopathy. Said medicine composition contains praestrene, nifurtair and mycostatin which can be used as active component and pharmaceutically-acceptable carrier. Said medicine composition can be made into the dosage forms, such as suppository, capsule, tablet, ointment and lotion suitable for intravaginal administration. Besides, said invention also provides its preparation method.

Description

field of invention [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating vaginal diseases, which uses nifuratel, nystatin and promestriene as active components. Background technique [0002] Gynecological vaginal diseases are common and frequently-occurring diseases in women, and trichomonas vaginitis, bacterial vaginosis and vulvovaginal candidiasis are more typical gynecological vaginal diseases, and their incidence rates are increasing year by year. There are many kinds of drugs available for the treatment of vaginal diseases clinically, but from the perspective of therapeutic effect and drug resistance, related preparations of nifuratel are a better choice. At present, the preparations of nifuratel in China are mainly The oral tablet of furatel, but the oral tablet of nifuratel has relatively large side effects, many adverse reactions, relatively poor relative effect, and low bioavailability. [0003] Cu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K9/02A61K9/06A61K9/08A61K9/20A61K9/48A61K31/422A61K31/565A61P15/02
Inventor 杨军
Owner BEIJING JINCHENG TAIER PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap